At a glance
ClinicalIndex Comparison RecordN/ACompleted· 37 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind Ketamine Augmentation in Chronically Suicidal, Treatment-resistant Major Depression
In Brief
A clinical study evaluating Ketamine and Placebo for Major Depressive Disorder. Completed, enrolled 37 participants across 1 site.
Detailed Summary
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous administration of ketamine in severely depressed, treatment resistant patients. The results of the study could lead to development of new strategies for treating depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 2012
Enrollment StartJan 2013
Primary CompletionOct 2015
Study CompletionNov 2015
TodayJul 2026
First PostedAug 17, 2012
Enrollment StartJan 1, 2013
Primary CompletionOct 1, 2015
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.9 years ago
Interventions
Ketaminedrug
ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.
Placebodrug